Kimia Therapeutics

Explore the latest insights on Kimia Therapeutics and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Kimia Therapeutics’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia
CompanyDeals

CStone Pharmaceuticals Partners with Kimia Therapeutics to Co‑Develop Potential First‑in‑Class DDR Inhibitor for Solid Tumors – CStone to Lead Phase I in Mainland China and Australia

CStone Pharmaceuticals (HKG: 2616) announced that it has entered into a collaboration agreement with Kimia Therapeutics, Inc., a biopharmaceutical company focused on innovative oncology and immunology therapies, to jointly advance…

GenFleet's Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors

GenFleet’s Oral Pan‑RAS Inhibitor GFH276 Clears Multiple CTAs in China and Australia – Innovative Combination Trials Advance Across RAS‑Mutant Solid Tumors

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

CMS Subsidiary Rxilient Medical Wins Singapore HSA Approval for Lumirix in Vitiligo – First Regional Indication Expansion for the Topical JAK Inhibitor Licensed from Incyte

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now